Tissue Core for Rapid Autopsy and Pancreatic Cancer Biorepository
Official title: Tissue Core-UNMC Rapid Autopsy Program
Funded at University of Oklahoma Hlth Sciences Ctr · NIH-11421832 · Data updated 2026-11-12
A centralized tissue and biofluid biorepository program collects and distributes deidentified human samples from pancreatic cancer patients and deceased donors to study how the cancer becomes resistant to treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project start | September 20, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $110,412 |
| NIH project number | 5U54CA274329-05 |
| Project ID | NIH-11421832 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are pancreatic cancer patients and deceased donors whose tissues and blood can be donated for research through established tissue banks and organ procurement networks.
✕Less likely to help
Patients whose tissues are not or cannot be donated, or whose data cannot be linked to outcomes, may see no direct benefit.
What this research studies
This grant funds a Tissue Core within ARTNet to procure, process, and share biological specimens and related clinical data from pancreatic cancer patients. The program includes rapid autopsy and collaboration with UNMC to build a longitudinal collection of tissue and biospecimens, including blood plasma and serum, spanning pre-diagnosis through end-stage disease. Researchers will access these deidentified samples to explore mechanisms of acquired resistance and enable translational studies that could inform future therapies. The core emphasizes coordinated, ethical sample handling, quality control, and data linking to clinical histories. Patients and families could benefit in the long term from advances in understanding resistance and developing new treatment options.
Why it matters
Potential benefit: If successful, the project could accelerate discoveries that lead to new therapies or strategies to overcome treatment resistance in pancreatic cancer.
How similar studies have gone: Previous biorepository efforts have enabled important insights into pancreatic cancer biology and resistance, though rapid autopsy programs are relatively specialized and outcomes can vary by center.
Where this research is happening
-
University of Oklahoma Hlth Sciences Ctr
Oklahoma City, United States Active
Researchers
- Principal investigator: Grandgenett, Paul M — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Grandgenett, Paul M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.